GC Therapeutics Appoints Stefan Irion as Chief Scientific Officer
GC Therapeutics (GCTx) has officially appointed Stefan Irion as its new Chief Scientific Officer (CSO). Irion brings over twenty years of experience in translating stem cell science into clinical-stage therapeutics. In his new role, he will lead the company’s research strategy and advance its differentiated cell therapy pipeline toward clinical application. This appointment follows the recent addition of Kate Haviland as Board Chair, signaling a strengthening of GCTx’s leadership team for its next growth phase. Concurrently, co-founder Alex Ng will transition to the role of chief innovation officer. Irion joins from BlueRock Therapeutics, a Bayer subsidiary, where he served as CSO and led a research organization of approximately 60 scientists developing cell and gene therapies. Parastoo Khoshakhlagh, CEO and Co-founder of GCTx, highlighted Irion’s deep expertise and patient commitment as key assets for driving the company forward. Irion expressed enthusiasm about continuing his career mission to bring cell therapies from bench to bedside. GC Therapeutics is a biotechnology firm focused on advancing next-generation cell-based medicines.
Wire timeline
GC Therapeutics Appoints Stefan Irion as Chief Scientific Officer
GC Therapeutics (GCTx) has officially appointed Stefan Irion as its new Chief Scientific Officer (CSO). Irion brings over twenty years of experience in translating stem cell science into clinical-stage therapeutics. In his new role, he will lead the company’s research strategy and advance its differentiated cell therapy pipeline toward clinical application. This appointment follows the recent addition of Kate Haviland as Board Chair, signaling a strengthening of GCTx’s leadership team for its next growth phase. Concurrently, co-founder Alex Ng will transition to the role of chief innovation officer. Irion joins from BlueRock Therapeutics, a Bayer subsidiary, where he served as CSO and led a research organization of approximately 60 scientists developing cell and gene therapies. Parastoo Khoshakhlagh, CEO and Co-founder of GCTx, highlighted Irion’s deep expertise and patient commitment as key assets for driving the company forward. Irion expressed enthusiasm about continuing his career mission to bring cell therapies from bench to bedside. GC Therapeutics is a biotechnology firm focused on advancing next-generation cell-based medicines.
PMLiVE